French immuno-oncology biotech OSE eyes an EU IPO

The U.S. boom in biotech IPOs has largely failed to drift across the Atlantic and galvanize many floats in Europe, but France's OSE Pharma is looking to buck that trend in hopes of bankrolling late-stage studies for its immuno-oncology candidate. As Reuters reports, OSE has registered with French regulators to stage an IPO of undisclosed value, planning to support Texopi, an immunotherapy for lung cancer. The drug met its goals in a Phase II study on 135 patients with non-small cell lung cancer, the company said, and now OSE needs about $25 million to begin late-stage development, which it hopes to commence in the second half of 2015, according to Reuters. More